Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
December 03, 2018 20:45 ET
|
Atara Biotherapeutics, Inc.
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustionMemorial Sloan Kettering...
Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
November 29, 2018 14:50 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
November 27, 2018 08:30 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
November 19, 2018 08:30 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
November 06, 2018 07:30 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
November 01, 2018 09:03 ET
|
Atara Biotherapeutics, Inc.
Moffitt Cancer Center collaborators to present next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustionMemorial Sloan Kettering...
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2018 16:55 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
September 11, 2018 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
September 06, 2018 07:30 ET
|
Atara Biotherapeutics, Inc.
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies Collaboration includes novel CAR T targeting and signaling domains designed to...
Atara Biotherapeutics to Participate at Two Upcoming Conferences
August 31, 2018 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments...